ABSTRACT:Objective: To investigate polypharmacy among the elderly living in the urban area of Florianopolis, in the state of Santa Catarina, Brazil, estimating the prevalence and associated factors. Methods: This is a crosssectional population-based study with a sample of 1,705 individuals aged 60 years old or older, between 2009 and 2010. The dependent variable was polypharmacy (defined as "use of five or more medications"). The following exploratory variables were utilized: sociodemographic data, use of health services and self-rated health status. Prevalence ratios (PR) were estimated by multivariate analysis using the Poisson regression. Results: The mean for the medications used by the elderly population was 3.8 (ranging from 0 to 28). The prevalence of polypharmacy was 32%, with 95% confidence interval (95% CI) 29.8 -34.3. The characteristics presenting a positive association with polypharmacy were: female gender (PR = 1.27; 95%CI 1.03 -1.57), increasing age (PR = 1.38; 95% CI 1.08 -1.77), negative self-rated health status (PR = 1.99; 95% CI 1.59 -2.48) and medical appointments in the 3 months prior to the interview (PR = 1.89; 95% CI 1.53 -2.32). The groups of medication most utilized by the elderly individuals in polypharmacy were those indicated for the cardiovascular system, digestive tract and metabolism, as well as the nervous system. Conclusion: The pattern of medication use among this elderly population is within the national average. The prevalence of polypharmacy and the characteristics associated with it were similar to those found in other regions of Brazil.

O presente estudo tem por objetivo descrever a prevalência, fatores associados e a forma de acesso aos medicamentos prescritos aos idosos residentes na área urbana do Município de Florianópolis, Santa Catarina, Brasil. Foi realizado estudo transversal populacional de base domiciliar em amostra de 1.469 indivíduos (taxa não-resposta 10,8%). Os dados foram analisados, por meio de regressão de Poisson, sob duas perspectivas: do acesso a medicamentos em geral e do acesso a medicamentos pelo SUS. Os resultados foram, respectivamente, 95,8% (IC95%: 94,7-96,8) e 50,3% (IC95%: 47,7-52,8). Observou-se que ocorre menor acesso a medicamentos quanto maior a dependência funcional, maior o número de doenças crônicas e quando há realização de consulta médica. Acessam mais medicamentos pelo SUS indivíduos de cor da pele parda ou negra, menor idade, pior escolaridade, pior renda, maior número de doenças crônicas, ausência de plano de saúde privado e consulta médica nos últimos três meses. Estes resultados mostram que o SUS vem cumprindo seu papel na universalização do acesso aos medicamentos em Florianópolis.

The aim of this study was to describe the medicines prescribed to elderly residents of Florianópolis, Santa Catarina State, Brazil,

Context Risk of cancer is a major concern in the development of drugs for the treatment of obesity and diabetes. In randomized controlled trials (RCTs) of the liraglutide development program, a glucagon-like peptide-1 receptor agonist (GLP-1RA), subjects treated with the active drug had a higher absolute number of breast cancer events. Objective To assess whether patients treated with GLP-1RAs had a higher risk of breast neoplasms. Data sources We searched MEDLINE, Embase, Web of Science, and CENTRAL from inception to February 8, 2020. Study Selection Reviewers assessed abstracts and full-text articles for RCTs of GLP-1RAs in adults with excessive weight and/or diabetes and a minimum follow-up of 24 weeks. Data extraction Researchers extracted study-level data and assessed within-study risk of bias with the RoB 2.0 tool and quality of evidence with GRADE. Data synthesis We included 52 trials, of which 50 reported breast cancer events and 11 reported benign breast neoplasms. Overall methodological quality was high. Among 48267 subjects treated with GLP-1RAs, 130 developed breast cancer compared to 107 of 40755 controls (relative risk [RR], 0.98; 95% confidence interval [CI], 0.76 to 1.26). Subset analyses according to follow-up, participant/investigator blinding, and type of GLP-1RA did not reveal any differences. The risk of benign breast neoplasms also did not differ between groups (RR, 0.99; 95% CI, 0.48 to 2.01). Trial sequential analysis provided evidence that the sample size was sufficient to avoid missing alternative results. Conclusions Treatment with GLP-1RAs for obesity and diabetes does not increase the risk of breast neoplasms.

Background: Risk of cancer is a major concern in the development of drugs for the treatment of obesity and diabetes. In randomized controlled trials (RCTs) of the liraglutide development program, a glucagon-like peptide-1 receptor agonist (GLP-1RA), subjects treated with the active drug had a higher absolute number of breast cancer events. Aim: To assess whether patients treated with GLP-1RAs had a higher risk of breast neoplasms. Methods: We searched MEDLINE, Embase, Web of Science, and CENTRAL from inception to February 8, 2020. Three pairs of reviewers examined and retrieved abstractsand full-text articles for RCTs of GLP-1RAs versus non-GLP-1RA controls(active or placebo) in adults with overweight, obesity, prediabetes, or diabetes,with a minimum follow-up period of 24 weeks and which reported at least oneevent of breast cancer or benign breast neoplasm. Divergences were dealt withby consensus. Researchers extracted study-level data and assessed within-study risk of bias with the RoB 2.0 tool and quality of evidence with GRADE. This study follows PRISMA reporting guidelines. Results: We included 52 trials, of which 50 reported breast cancer events and 11 reported benign breast neoplasms. Overall methodological quality was high. Among 48267 subjects treated with GLP-1RAs, 130 developed breast cancer compared to 107 of 40755 controls (relative risk [RR], 0.98; 95% confidence interval [CI], 0.76 to 1.26). Subset analyses according to follow-up, participant/investigator blinding, and type of GLP-1RA did not reveal any differences. The risk of benign breast neoplasms also did not differ between groups (RR, 0.99; 95% CI, 0.48 to 2.01). Trial sequential analysis provided evidence that the sample size was sufficient to avoid missing alternative results. Conclusion: Treatment with GLP-1RAs for obesity and diabetes does not increase the risk of breast neoplasms. Register: This systematic review was preregistered in PROSPERO (CRD42019132704).

O elenco de medicamentos fornecidos em caráter ambulatorial pela Secretaria de Estado da Saúde do Rio Grande do Sul (SES/RS) contemplava todos medicamentos incorporados pelo Ministério da Saúde (MS) no Componente Especializado de Assistência Farmacêutica (CEAF). Porém, verificou-se a necessidade de revisão deste elenco, com base no perfil e nas necessidades da população do Estado, com o objetivo de racionalizar e ampliar o acesso aos medicamentos essenciais. A Comissão de Farmácia e Terapêutica da SES/RS elaborou um método técnico-científico de avaliação deste elenco, baseado nas linhas de cuidado dos Protocolos Clínicos e Diretrizes Terapêuticas (PCDT) do MS, com o objetivo de construir a Relação Estadual de Medicamentos com maior racionalidade e eficiência administrativa, incluindo os medicamentos considerados essenciais no Estado do Rio Grande do Sul. A partir deste método, medicamentos foram classificados conforme grupo de financiamento do CEAF, classe farmacológica e via de administração, além de possíveis especificidades técnicas que os tornam indispensáveis dentro de cada linha de cuidado, e após foram comparados às possíveis alternativas terapêuticas dentro de cada PCDT. Além disso, foi considerado o histórico da demanda do medicamento na SES/RS, a possibilidade atual de compra e o seu custo comparado às alternativas terapêuticas. Houve recomendação de exclusão de 37 (11,4%) itens, sem que houvesse prejuízo no tratamento dos pacientes. Todos os medicamentos excluídos da REME possuem alternativa terapêutica da mesma classe farmacológica e forma farmacêutica dentro da linha de cuidado.

IntroductionIn Brazil, hospital-based health technology assessment (HB-HTA) units have been implemented countrywide since early 2000 to improve decision-making processes. Multiple-criteria decision analysis (MCDA) can provide a deeper understanding of a given subject. The present study used MCDA to evaluate capacity building among HB-HTA units in Brazil.MethodsThis study analyzed preliminary data from a survey developed and sent to all HB-HTA units in Brazil in 2018. The survey comprised 116 questions covering a wide range of aspects. Initially, an expert panel was organized, and 46 objective questions (out of 116) were selected by four experts. Next, these experts classified the selected questions by weighting them according to their relative importance. A Likert scale was used to identify the levels of importance, which were converted to weights ranging from zero to one. The experts then defined a final importance score threshold of 60 percent to classify units as fully operational. Grades below this threshold indicated the need for a more detailed evaluation. Of the 80 survey questionnaires, 23 were evaluated by the proposed method.ResultsImportance weights for each classification were defined as follows: personnel (25%); level of expertise (31%); work production (31%); and infrastructure (13%). The mean final importance score for the HB-HTA units was 68 percent. The maximum and minimum scores achieved were 95 percent and 15 percent, respectively. The HB-HTA units had been established for an average of 6 years, and ten of the 23 units were classified as fully operational.ConclusionsThe multicriteria method presented by this study simplified HB-HTA unit evaluation, reducing the subjectivity of results. Final importance scores for each unit's categories indicated which areas need improvement. Results from the study indicated that infrastructure and personnel could be greatly enhanced, even though the production profile was satisfactory.

IntroductionSince 2007, 23 Núcleos de Avaliação de Tecnologias em Saúde or hospital-based health technology assessment (HB-HTA) units have been established in teaching hospitals across Brazil. These units aim to promote the development of health technology assessment in hospitals, assisting the decision-making process for implementing new technologies and evaluating and promoting the rational use of widespread technologies.MethodsAn online questionnaire was sent by e-mail to all HB-HTA units registered in the Brazilian Network for Evaluation of Health Technologies. Information was acquired to comprehensively assess the activity of the units.ResultsAll 23 HB-HTA units answered the questionnaire. Of these, 65 percent had a technology prioritization process. The technologies assessed included drug therapies (73%), equipment (64%), medical devices (64%), clinical protocols (46%), and emerging technologies (27%). The dimensions of health technology assessment (HTA) evaluated by these organizations were: efficacy (76%); effectiveness (67%); safety (67%); costs (52%); cost effectiveness or cost utility (52%); and budget impact (43%). The hospital departments that required more HTA studies were: cardiology (50%); infectious diseases (45%); hospital management (45%); oncology (40%); surgery (40%); and endocrinology (20%). HTA studies supported: incorporation of new technologies (81%); protocol or guideline development (57%); new indications for already approved technologies (38%); and withdrawal of obsolete technologies (29%). Half of the institutions also conducted educational or training activities. The main difficulties reported were a lack of trained professionals (78%), funding (70%), and material resources (48%).ConclusionsFor low- and middle-income countries, the process of implementing HB-HTA units remains a challenge. Even though human resources and funding are scarce, HB-HTA units continue to develop. Given their importance in the decision-making process, it is imperative that every effort is made to ensure their activities continue.